KAIST: New Therapy Turns Tumor Macrophages into Cancer Fighters | ACS Nano Publication

The fight against cancer may have a powerful new ally: the body’s own immune system, specifically immune cells residing within tumors. Researchers at the Korea Advanced Institute of Science and Technology (KAIST) have announced a breakthrough in immunotherapy, successfully reprogramming immune cells already present in tumors to actively target and destroy cancer cells. This approach bypasses a major hurdle in cancer treatment – the difficulty of getting immune cells to infiltrate and function effectively within solid tumors.

For decades, scientists have understood that tumors aren’t simply masses of rogue cells, but complex ecosystems that actively suppress the immune system. Macrophages, a type of white blood cell normally tasked with attacking foreign invaders and clearing debris, are often abundant within tumors. However, these macrophages are frequently “silenced” by the tumor environment, effectively becoming bystanders instead of soldiers. The KAIST team, led by Professor Ji-Ho Park of the Department of Bio and Brain Engineering, has found a way to reverse this process, transforming these dormant cells into potent cancer fighters.

Reprogramming Macrophages with Targeted Delivery

The core of this new therapy lies in a specially designed drug delivered directly into tumors. When injected, the drug is absorbed by the tumor-associated macrophages. Crucially, this isn’t about introducing new immune cells into the body; it’s about reactivating and repurposing those already on site. Once inside the macrophages, the drug triggers the production of CAR (chimeric antigen receptor) proteins. These CAR proteins act as “cancer-recognizing devices,” enabling the macrophages – now dubbed “CAR-macrophages” – to identify and bind to cancer cells. ScienceDaily details how this process effectively turns the tumor’s own defenses against it.

Why Solid Tumors Pose a Unique Challenge

Solid tumors, including cancers of the lung, liver, and stomach, present a particularly challenging challenge for immunotherapy. Their dense structure creates a physical barrier, preventing immune cells from easily penetrating the tumor mass. Even when immune cells do reach the tumor, the immunosuppressive environment often renders them ineffective. Existing immunotherapies, even as successful in some cases, often struggle to overcome these obstacles. The KAIST approach directly addresses this issue by working within the tumor’s existing architecture, utilizing the macrophages already present.

Beyond Conventional CAR-Macrophage Therapy

CAR-macrophage therapy isn’t entirely new, but traditional methods have significant limitations. Conventional approaches require extracting a patient’s immune cells, genetically modifying them in a lab to express CAR proteins, and then re-infusing them back into the body. This process is time-consuming, expensive, and not readily scalable for widespread clinical leverage. KAIST News highlights that the new method circumvents these hurdles by directly converting macrophages inside the tumor, eliminating the need for external cell manipulation.

How the New Therapy Works: Lipid Nanoparticles and mRNA

The researchers achieved this direct reprogramming using lipid nanoparticles. These tiny particles are readily absorbed by macrophages and carry two key components: mRNA encoding the cancer-recognition information for the CAR proteins, and an immune-boosting compound. The mRNA instructs the macrophages to produce the CAR proteins, while the immune-boosting compound activates the cells, enhancing their anticancer activity. This dual action results in “enhanced CAR-macrophages” with significantly improved cancer-killing capabilities. The study, published in ACS Nano, demonstrates that these enhanced cells not only destroy cancer cells directly but also stimulate surrounding immune cells, amplifying the overall immune response.

Promising Results in Animal Models

Initial testing of the therapy in animal models of melanoma, a particularly aggressive form of skin cancer, yielded encouraging results. Tumor growth was significantly reduced in treated animals, and the immune response appeared to extend beyond the injected tumor, suggesting the potential for broader, systemic protection. While these results are promising, it’s crucial to remember that animal studies don’t always translate directly to humans. Further research and clinical trials are necessary to determine the therapy’s safety and efficacy in human patients.

CAR-Macrophages: A Multifaceted Attack

CAR-macrophages offer a unique advantage over some other immunotherapies. Unlike T-cells, which primarily kill cancer cells directly, macrophages can also engulf and digest them – a process known as phagocytosis. Macrophages play a crucial role in activating other immune cells, creating a more robust and coordinated anticancer response. This multifaceted attack makes CAR-macrophages a particularly attractive target for next-generation immunotherapy.

What Comes Next: Clinical Trials and Further Research

Professor Ji-Ho Park emphasizes that this study represents a “new concept of immune cell therapy” that overcomes key limitations of existing approaches. The next step is to translate these findings into clinical trials to evaluate the therapy’s safety and effectiveness in human patients. Researchers will also focus on optimizing the lipid nanoparticle delivery system and exploring the potential of this approach for treating other types of solid tumors. EurekAlert! reports that the research was supported by the Mid-Career Researcher Program of the National Research Foundation of Korea, indicating ongoing investment in this promising area of cancer research. The success of these trials will determine whether this innovative approach can become a viable treatment option for cancer patients in the future.